Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJ-Neo006 + Camrelizumab in Resectable Pancreatic Cancer
NCT06326736Phase 1Recruiting
- Sponsor
- Jinling Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SJ-Neo006 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Jinling Hospital. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
SJ-Neo006
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06326736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326736.